GLP-1 Peptides Explained: Semaglutide, Tirzepatide, Retatrutide & Liraglutide

For research and educational purposes only. This content does not constitute medical advice. Peptides discussed here are intended for laboratory and academic research. Consult the regulatory framework governing your institution and jurisdiction before sourcing any research compound.

Few areas of peptide science have attracted as much sustained scientific and commercial interest as glucagon-like peptide-1 (GLP-1) receptor agonism. Over the past two decades, the GLP-1 class has moved from obscure academic discovery to the center of global metabolic research — with Semaglutide alone becoming one of the most prescribed compounds in modern medicine. Yet despite widespread media coverage, the underlying receptor biology, structural pharmacology, and comparative research profiles of these compounds remain poorly understood outside specialist circles.

This guide provides a rigorous, research-framed comparison of the four key compounds in the GLP-1 family: Liraglutide, Semaglutide, Tirzepatide, and Retatrutide. It is structured for researchers, science communicators, and informed readers who want to understand these compounds at the mechanistic and structural level, beyond the clinical headlines.

For a broader introduction to the peptide research landscape, see our Complete Guide to Peptide Research in 2026.

The GLP-1 Receptor: Mechanism of Action

GLP-1 (glucagon-like peptide-1) is a 30-amino acid incretin hormone encoded within the proglucagon gene and secreted primarily by L-cells in the small intestinal mucosa in response to nutrient ingestion. It acts through a specific G protein-coupled receptor (GPCR) — the GLP-1 receptor (GLP-1R) — expressed across multiple tissue types, most prominently pancreatic beta cells, hypothalamic neurons, the vagus nerve, and cardiac tissue.

Receptor Signaling Cascade

When GLP-1 or a GLP-1R agonist binds to GLP-1R, it activates adenylyl cyclase through the Gαs signaling pathway, increasing intracellular cyclic AMP (cAMP). Elevated cAMP drives multiple downstream effects:

• Pancreatic beta cells: Augmented glucose-stimulated insulin secretion (GSIS), reduced glucagon release from alpha cells
• Hypothalamus and brainstem: Appetite-regulating signals acting through the arcuate nucleus and nucleus tractus solitarius
• Gastrointestinal tract: Slowed gastric emptying, reduced intestinal motility
• Cardiovascular tissue: Research has documented cardioprotective signaling in preclinical and clinical settings

The critically important feature of GLP-1R-mediated insulin secretion is its glucose dependence — the receptor potentiates insulin release only when plasma glucose is elevated. This glucose-dependent mechanism has been central to the safety profile research on this drug class.

Why GLP-1 Itself Has Limited Research Utility

Native GLP-1(7-36) amide — the active endogenous form — has a plasma half-life of less than two minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance. This makes it impractical as a research or therapeutic tool without chemical modification. The entire GLP-1 agonist drug class was built around solving this stability problem. Each compound in the family represents a different structural solution.

Timeline of Discovery: From Exendin-4 to Multi-Agonism

Understanding the GLP-1 class requires following the timeline of discovery:

1983–1987: GLP-1 identified as a product of proglucagon processing; incretin effect established in the literature.

1992: Exendin-4, a GLP-1R agonist found in Gila monster venom, identified by John Eng at the VA Medical Center in New York. Exendin-4 shares approximately 53% sequence homology with human GLP-1 but is resistant to DPP-4 degradation — the key property that made it the prototype for the entire drug class.

2005: Exenatide (synthetic exendin-4) becomes the first GLP-1 receptor agonist approved by the FDA, under the brand name Byetta.

2009: Liraglutide enters clinical use — the first human GLP-1 analogue (as opposed to the non-human exendin-4 scaffold), with a fatty acid modification enabling albumin binding and extended half-life.

2012–2021: Semaglutide developed with further structural optimization — a larger, more structured fatty diacid modification extending half-life to approximately one week, enabling once-weekly administration. Later, oral formulation (Rybelsus) demonstrated that GLP-1R agonists could achieve meaningful bioavailability via the gastrointestinal route with appropriate formulation technology (SNAC absorption enhancer).

2022–2023: Tirzepatide achieves regulatory approval — representing a paradigm shift from single-receptor to dual-receptor agonism (GLP-1R + GIPR). Clinical trials demonstrated effect sizes exceeding those of any previous compound in this class.

2023–present: Retatrutide advances through clinical trials as a triple agonist (GLP-1R + GIPR + GcgR), representing the current frontier of multi-receptor metabolic research. Phase 2 trial data published in the New England Journal of Medicine in 2023 generated significant scientific interest.

Liraglutide: The Human Analogue Prototype

Liraglutide is a 97% homologous analogue of human GLP-1, with two structural modifications that distinguish it from the native hormone: a substitution at position 34 (arginine replaces lysine) that eliminates DPP-4 recognition, and a C16 fatty acid chain (palmitic acid) attached via a glutamic acid linker to lysine at position 26. This fatty acid side chain facilitates reversible non-covalent binding to albumin in plasma, extending the effective half-life to approximately 11–15 hours — sufficient for once-daily administration.

Research Profile

Liraglutide's value as a research compound lies partly in its status as the most extensively studied human GLP-1 analogue. Decades of published literature have characterized its receptor binding kinetics, receptor internalization dynamics, cardiovascular signaling (the LEADER trial published cardiovascular outcomes data that influenced the entire field), and renal biology.

For researchers comparing GLP-1 analogues, liraglutide serves as a benchmark — its receptor selectivity, efficacy data, and safety profile provide a well-characterized reference point against which newer multi-agonist compounds can be evaluated.

Semaglutide: Structural Sophistication and Extended Half-Life

Semaglutide emerged from the search for a GLP-1 analogue capable of once-weekly dosing. Two key structural modifications achieve this:

1. Alpha-aminoisobutyric acid (Aib) substitution at position 8: Replaces alanine, which is the primary DPP-4 cleavage site, with a non-natural alpha-methyl amino acid that sterically blocks DPP-4 access
2. C18 fatty diacid modification at position 34: A more complex and extended fatty acid structure than liraglutide's palmitic chain, resulting in stronger albumin binding and a plasma half-life of approximately 165–184 hours (~one week)

This fatty acid structure also gives semaglutide a distinct three-dimensional presentation at the receptor binding interface. Structural studies using cryo-electron microscopy have characterized the semaglutide-GLP-1R complex in detail, showing how the fatty acid chain interacts with a hydrophobic groove in the receptor's extracellular domain.

Research Profile

Semaglutide has been studied across a broader range of contexts than any other GLP-1 agonist — metabolic function, cardiovascular biology (SELECT trial data), nephrology, neurological function (FLOW trial), and body composition research. It has also been used in preclinical models studying addiction biology, neuroinflammation, and fatty liver disease. The breadth of its published research record makes it particularly valuable as a research tool.

For researchers evaluating semaglutide alongside Tirzepatide or Retatrutide, the structural comparison is instructive: semaglutide's selectivity for GLP-1R alone provides a clean baseline for isolating GLP-1R-specific signaling.

Tirzepatide: Dual GLP-1R/GIPR Agonism

Tirzepatide represents a fundamental departure from the single-target paradigm of earlier GLP-1 agonists. It is a 39-amino acid synthetic peptide — not a modification of native GLP-1 — designed to activate both GLP-1R and the glucose-dependent insulinotropic polypeptide receptor (GIPR) with high potency.

The GIPR Contribution

GIP (glucose-dependent insulinotropic polypeptide) is the other principal incretin hormone, also secreted in response to nutrient ingestion, acting through GIPR. Historically, the GIP system was considered less attractive for metabolic pharmacology than GLP-1 — partly because GIPR agonism was paradoxically associated with some pro-adipogenic effects in isolation. However, when combined with GLP-1R agonism, the combined activation of GLP-1R and GIPR has demonstrated a synergistic effect in preclinical and clinical research.

The mechanistic hypothesis is that combined GLP-1R/GIPR co-activation produces complementary downstream signaling — GIPR agonism may partially offset GLP-1R-mediated nausea pathways while amplifying the metabolic effects through additive beta-cell stimulation and hypothalamic satiety signaling.

Structural Design

Tirzepatide's sequence is based on the GIP peptide backbone (not GLP-1), with modifications to introduce GLP-1R cross-reactivity, DPP-4 resistance, and albumin-mediated half-life extension via a C20 fatty diacid. This "GIP-derived dual agonist" architecture distinguishes tirzepatide from earlier attempts at dual agonism, which typically used GLP-1 as the backbone.

Research Profile

Phase 3 SURPASS trial data demonstrated metabolic effects exceeding those of semaglutide in head-to-head comparisons (SURPASS-2 trial). Mechanistic research using tirzepatide as a research tool has helped the field understand which effects are attributable to GLP-1R activation alone versus combined GLP-1R/GIPR co-activation. Researchers in metabolic biology use tirzepatide alongside semaglutide for this discriminatory purpose.

Retatrutide: Triple Agonism and the Research Frontier

Retatrutide adds a third receptor target to the dual-agonist framework: the glucagon receptor (GcgR). This makes it a GLP-1R / GIPR / GcgR triple agonist — sometimes referred to informally as a "triple G" agonist in the research literature.

The Glucagon Receptor Contribution

Glucagon acts on GcgR to increase hepatic glucose production and stimulate lipolysis (fat breakdown). In metabolic biology, this appeared counterintuitive as a target for compounds studied in the context of metabolic health — glucagon's effects on blood glucose seem directionally problematic when combined with GLP-1's glucose-lowering actions. However, research has found that GcgR agonism in the context of GLP-1R co-activation has a net thermogenic and lipolytic effect, particularly in adipose tissue and the liver, without the unwanted systemic hyperglycemia.

The mechanistic hypothesis is that GcgR activation at the hepatic level drives fatty acid oxidation and energy expenditure in a way that complements the GLP-1R/GIPR-mediated effects on satiety and insulin secretion. This three-receptor combination creates a research model unlike any prior pharmacological tool.

Research Profile

Phase 2 trial data for retatrutide published in the New England Journal of Medicine (2023) demonstrated pronounced effects on body weight and adipose biology in a 48-week trial — findings that catalyzed substantial academic and commercial interest in the triple-agonist approach. The mechanistic understanding of how GcgR co-activation interacts with GLP-1R and GIPR signaling is an active research area.

Comparing the Four Compounds: A Structural Summary

Why Researchers Compare These Compounds

The progressive addition of receptor targets across this compound series has made GLP-1 peptide research one of the most powerful natural experiments in modern pharmacology. By studying these compounds in parallel — in cell-based assays, animal models, or reviewing clinical trial data — researchers can dissect which biological effects are mediated by which receptor pathway.

For example, comparing the body composition effects of semaglutide (GLP-1R only) with tirzepatide (GLP-1R + GIPR) allows researchers to attribute the incremental effect to GIPR co-activation. Comparing tirzepatide with retatrutide allows isolation of the GcgR contribution.

This type of pharmacological dissection is a core research application for the GLP-1 peptide family. Research suppliers such as Practically Natty Peptides can be a resource for accessing research-grade GLP-1 peptides with the purity documentation needed for experimental use.

For guidance on evaluating supplier documentation and purity standards, see our 7-point peptide supplier checklist.

Conclusion

The GLP-1 peptide family has progressed from a single naturally occurring incretin to a sophisticated toolkit of engineered receptor agonists targeting one, two, or three distinct GPCR pathways. Each compound represents a unique pharmacological probe for metabolic biology, cardiovascular function, neurological signaling, and beyond.

Researchers engaging with this class should understand the structural basis for each compound's receptor selectivity profile, the clinical evidence base, and the mechanistic hypotheses guiding ongoing investigation. The individual peptide pages for Semaglutide, Tirzepatide, Retatrutide, and Liraglutide on PeptiDex provide detailed profiles of each compound's research literature.

For research and educational purposes only. Not medical advice. All peptides described on this site are intended for laboratory research use only.